# The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca

Source: https://onco.cc/trials/nct05984485/  
OnCo record `nct05984485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT05984485 by Sun Yat-sen University, with a registry enrolment figure of 766 participants, started 2022-07-05 and due to reach its primary completion in 2028-07. Interventions recorded: neoadjuvant chemotherapy plus total mesorectal excision; total mesorectal excision. Conditions listed: Rectal Cancer. Primary outcome: 3-year Disease Free Survival. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TaLaR-02
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05984485
- Phase: 3
- Setting: TME vs TME+nCT in Low-risk LARC
- Sponsor: Sun Yat-sen University
- Enrolled: 766

## Sources

- ClinicalTrials.gov NCT05984485: https://clinicaltrials.gov/study/NCT05984485

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05984485.json